Not Yet RecruitingPhase 1/2

Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

3 participantsStarted 2026-04-05

Plain-language summary

This study is an open-label, single-arm, prospective, exploratory clinical trial involving patients with relapsed/refractory large B-cell lymphoma, aiming to preliminarily assess the safety and efficacy of CAR-T cell infusion.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Creatinine ≤ 1.5×ULN;
✓. Left ventricular ejection fraction ≥ 50%;
✓. Blood oxygen saturation \> 90%;
✓. Total bilirubin ≤ 1.5×ULN; ALT and AST ≤ 2.5×ULN;

What they're measuring

Incidence and severity of adverse events

Timeframe: Within 28 days after CAR-T infusion

Trial details

NCT IDNCT07447726

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-01-01

Contact for this trial

Liang Huang

02223608359 huangliang@ihcams.ac.cn

View on ClinicalTrials.gov More Large B-Cell Lymphoma (LBCL) trials